Form 8-K - Current report:
SEC Accession No. 0001193125-22-158049
Filing Date
2022-05-24
Accepted
2022-05-24 08:23:01
Documents
14
Period of Report
2022-05-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d355002d8k.htm   iXBRL 8-K 24078
2 EX-99.1 d355002dex991.htm EX-99.1 9802
6 GRAPHIC g355002g0524075249760.jpg GRAPHIC 6424
  Complete submission text file 0001193125-22-158049.txt   168681

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alpn-20220524.xsd EX-101.SCH 2897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alpn-20220524_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alpn-20220524_pre.xml EX-101.PRE 11289
8 EXTRACTED XBRL INSTANCE DOCUMENT d355002d8k_htm.xml XML 3359
Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Filer) CIK: 0001626199 (see all company filings)

EIN.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37449 | Film No.: 22954070
SIC: 2834 Pharmaceutical Preparations